By Chris Wack


Monopar Therapeutics Inc. shares rose 12% to $5.10 in premarket trading after the company said the first patient has been dosed in its open-label dose-escalation Phase 1b clinical trial evaluating camsirubicin for the treatment of advanced soft tissue sarcoma.

The biopharmaceutical company received U.S. Food and Drug Administration allowance to proceed in early August.

Monopar said an estimated 21 patients will be enrolled in the Phase 1b clinical trial, which is active and recruiting in the U.S.


Write to Chris Wack at


(END) Dow Jones Newswires

October 27, 2021 09:24 ET (13:24 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.